Latest News

With a median price-to-earnings (or "P/E") ratio of close to 23x in India, you could be forgiven for feeling...

While SJVN Limited ( NSE:SJVN ) shareholders are probably generally happy, the stock hasn't had particularly good run...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

Unfortunately for some shareholders, the Inox Green Energy Services Limited ( NSE:INOXGREEN ) share price has dived 25...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

With a price-to-earnings (or "P/E") ratio of 19x Galaxy Entertainment Group Limited ( HKG:27 ) may be sending very...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Key Insights Insiders appear to have a vested interest in Great Rich Technologies' growth, as seen by their sizeable...

JK Synapse Co., Ltd. ( KOSDAQ:060230 ) shares have had a really impressive month, gaining 33% after a shaky period...

Genscript Biotech (SEHK:1548) is back in focus after its associate Legend Biotech reported approximately US$555 million in Q4 2025 net trade sales of multiple myeloma cell therapy CARVYKTI®, underscoring meaningful commercial traction. See our latest analysis for Genscript Biotech. Legend Biotech’s CARVYKTI® sales update has arrived after a mixed year for Genscript Biotech, with the share price at HK$13.3, a year to date share price return of 3.99%, a 1 year total shareholder return of 26.19%...

Altimmune recently received FDA Breakthrough Therapy Designation for its investigational drug pemvidutide after mid‑stage data showed significant MASH resolution, and the company plans a 52‑week late‑stage trial to test multiple doses. This designation could shorten regulatory timelines and enhance pemvidutide’s profile in the competitive MASH treatment landscape, potentially reshaping Altimmune’s long‑term product mix and risk profile. Next, we’ll examine how pemvidutide’s Breakthrough...

National HealthCare Corporation recently reached a record high level after reporting 22.67% revenue growth over the past year and declaring a US$0.64 quarterly dividend per share, underscoring its focus on returning cash to shareholders. The company’s ‘GREAT’ financial health score, combined with strong recent results and ongoing dividend payments, may be reinforcing investor confidence in its operational resilience. We’ll now examine how National HealthCare’s robust revenue growth and...

When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 15x, you may consider Tokyo...

Most readers would already be aware that Nikon's (TSE:7731) stock increased significantly by 13% over the past month...

Trend Micro (TSE:4704) has had a rough three months with its share price down 21%. However, stock prices are usually...

Capricorn Metals (ASX:CMM) has had a great run on the share market with its stock up by a significant 19% over the last...

In January 2026, Interroll announced the departure of Chief Operating Officer Ayan Demirel and Chief Technology Officer Dr. Johannes Van Der Beek, with CEO Markus Asch temporarily assuming operational leadership and industry veteran Ulrich Engenhardt joining as the new CTO. These simultaneous changes in operations and technology leadership highlight a pivotal moment for Interroll’s organisational direction, particularly around product platforms, regional capabilities and innovation...

In recent months, analysts have become more positive on The RealReal after the company reported past third-quarter results that outpaced forecasts for revenue and adjusted EBITDA. Alongside this, The RealReal’s introduction of its Athena AI system to support authentication, descriptions, and pricing underscores a push toward greater efficiency in its luxury resale operations. Next, we’ll explore how this combination of analyst confidence and Athena-driven operational enhancement shapes The...

Production update and why it matters for CGN Mining CGN Mining (SEHK:1164) has released unaudited natural uranium production figures, reporting 702.5 tU for the fourth quarter of 2025 and 2,699.0 tU for the full year. This provides investors with fresh insight into recent operating performance. See our latest analysis for CGN Mining. The production update lands after a strong run in the shares. The latest HK$4.3 price comes alongside a 32.72% year to date share price return and a very large 5...